Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 75 results:
Συντάκτης [ Τίτλος(Desc)] Τύπος Έτος
Φίλτρα: Συντάκτης is Bobos, Mattheos  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
P
Fountzilas, G., Fragkoulidi A., Kalogera-Fountzila A., Nikolaidou M., Bobos M., Calderaro J., et al. (2010).  A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer.. Cancer Chemother Pharmacol. 65(4), 649-60.
Gogas, H., Dafni U., Karina M., Papadimitriou C., Batistatou A., Bobos M., et al. (2012).  Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial.. Breast Cancer Res Treat. 132(2), 609-19.
Fostira, F., Tsitlaidou M., Papadimitriou C., Pertesi M., Timotheadou E., Stavropoulou A. V., et al. (2012).  Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study.. Breast Cancer Res Treat. 134(1), 353-62.
Fountzilas, G., Psyrri A., Giannoulatou E., Tikas I., Manousou K., Rontogianni D., et al. (2018).  Prevalent somatic BRCA1 mutations shape clinically relevant genomic patterns of nasopharyngeal carcinoma in Southeast Europe.. Int J Cancer. 142(1), 66-80.
Pectasides, E., Chatzidakis I., Kotoula V., Koliou G-A., Papadopoulou K., Giannoulatou E., et al. (2020).  Prognostic Biomarkers in Early-stage Gastric Adenocarcinoma Treated With Adjuvant Chemoradiotherapy.. Cancer Genomics Proteomics. 17(3), 277-290.
Fountzilas, E., Kotoula V., Pentheroudakis G., Manousou K., Polychronidou G., Vrettou E., et al. (2019).  Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancer.. ESMO Open. 4(2), e000474.
Koumarianou, A., Tzeveleki I., Mekras D., Eleftheraki A. G., Bobos M., Wirtz R., et al. (2014).  Prognostic markers in early-stage colorectal cancer: significance of TYMS mRNA expression.. Anticancer Res. 34(9), 4949-62.
Pentheroudakis, G., Kotoula V., Eleftheraki A. G., Tsolaki E., Wirtz R. M., Kalogeras K. T., et al. (2013).  Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG).. PLoS One. 8(7), e70634.
Psyrri, A., Kotoula V., Fountzilas E., Alexopoulou Z., Bobos M., Televantou D., et al. (2014).  Prognostic significance of the Wnt pathway in squamous cell laryngeal cancer.. Oral Oncol. 50(4), 298-305.
Pentheroudakis, G., Batistatou A., Kalogeras K. T., Kronenwett R., Wirtz R. M., Bournakis E., et al. (2011).  Prognostic utility of β-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study.. Breast Cancer Res Treat. 127(1), 179-93.
Krikelis, D., Kotoula V., Bobos M., Fountzilas E., Markou K., Karasmanis I., et al. (2014).  Protein and mRNA expression of notch pathway components in operable tumors of patients with laryngeal cancer.. Anticancer Res. 34(11), 6495-503.
Zagouri, F., Kotoula V., Kouvatseas G., Sotiropoulou M., Koletsa T., Gavressea T., et al. (2017).  Protein expression patterns of cell cycle regulators in operable breast cancer.. PLoS One. 12(8), e0180489.
T
Kostopoulos, I., Karavasilis V., Karina M., Bobos M., Xiros N., Pentheroudakis G., et al. (2009).  Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy.. BMC Cancer. 9, 339.
Fountzilas, G., Christodoulou C., Bobos M., Kotoula V., Eleftheraki A. G., Xanthakis I., et al. (2012).  Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab.. J Transl Med. 10, 212.
Fountzilas, G., Giannoulatou E., Alexopoulou Z., Zagouri F., Timotheadou E., Papadopoulou K., et al. (2016).  TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.. Oncotarget. 7(22), 32731-53.
Christodoulou, C., Kostopoulos I., Kalofonos H. P., Lianos E., Bobos M., Briasoulis E., et al. (2009).  Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. phase II Study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation.. Oncology. 76(4), 275-85.
Hatzibougias, D. I., Fouzas I., Bobos M., Papanikolaou V., Daoudaki M., Kotoula V., et al. (2016).  Tubular Pyloric Gland Adenoma of the Left and Right Hepatic Ducts: Report of a Unique Case With Immunohistochemical and Molecular Studies.. Int J Surg Pathol. 24(4), 347-52.
Nikolaidi, A., Kotoula V., Koliou G-A., Giannoulatou E., Papadopoulou K., Zagouri F., et al. (2020).  Tumor Mutational Patterns and Infiltrating Lymphocyte Density in Young and Elderly Patients With Breast Cancer.. Cancer Genomics Proteomics. 17(2), 181-193.
Kotoula, V., Chatzopoulos K., Lakis S., Alexopoulou Z., Timotheadou E., Zagouri F., et al. (2016).  Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials.. Oncotarget. 7(4), 5074-87.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.